Evaluation of the artificial intelligence (AI) for predicting optimized insulin dosage in diabetic patients

JRCT ID: jRCT1022240017

Registered date:07/08/2024

Basic Information

• Recruitment status: Pending
• Health condition(s) or Problem(s) studied: Type 2 Diabetes
• Date of first enrollment: 07/08/2024
• Target sample size: 130
• Study type: Observational

Outcome(s)

• Primary Outcome: Correct rate: Rate when the difference between the test device and the units prescribed by diabetologists is within the acceptable range.

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

Clinical data of hospitalized type 2 diabetes patients who received insulin therapy from diabetologists will be collected, provided they meet all the following eligibility criteria and do not fall under any exclusion criteria.
Eligibility Criteria:
(1) Patients using ultra-rapid-acting insulin and long-acting insulin (insulin glargine, insulin degludec)
(2) Patients aged 20 years or older
(3) Patients who have provided written consent to participate in the study
(4) Patients with a hospital stay of 7 days or more

Exclude criteria

(1) Patients who are pregnant or may be pregnant
(2) Patients with or suspected of having diabetic gastroparesis
(3) Patients with severe diabetic autonomic neuropathy
(4) Patients with pre-proliferative diabetic retinopathy or proliferative diabetic retinopathy, or suspected of having these conditions
(5) Patients undergoing continuous subcutaneous insulin infusion therapy or continuous intravenous insulin infusion
(6) Patients who have not been discharged since undergoing general anesthesia surgery
(7) Patients with missing data in the specified input data without any reason such as tests
(8) Patients whose primary purpose is not blood glucose control
(9) For cases from Tohoku University Hospital, data from hospitalizations before 2021 (as these data may have been used for the training of the experimental device)

Related Information

• Primary Sponsor: Katagiri Hideki
• Source(s) of Monetary Support: AMED,Renascience Inc.